Foundation
Medicine today announced a new agreement with Novartis to provide
comprehensive genomic analysis in support of Novartis' clinical oncology
programs.
Novartis plans to use Foundation Medicine's molecular information
platform across many of Novartis' Phase 1 and 2 oncology clinical
programs. The pilot program established between Novartis and Foundation
Medicine 18 months ago has generated very interesting data, and this
type of tumor genomic profiling has become an essential component of
Novartis' clinical trials. The partnership consists of running
Foundation Medicine's comprehensive genomic profiling on most Phase 1
and 2 clinical trial enrollees over the next three years. The
partnership aims to accelerate the development of Novartis' broad
portfolio of targeted cancer therapeutics and ultimately expand
treatment options for patients.
"The comprehensive molecular assessment of Novartis' Oncology clinical
trial samples is expected to help to bring potentially lifesaving
therapies to the right patients more quickly, and we expect that the
wealth of molecular information will help fundamentally improve the way
cancer is understood and treated," said Michael J. Pellini, M.D.,
president and CEO, Foundation Medicine. "We are pleased to see our
collaboration mature into a significant relationship between Foundation
Medicine and Novartis."
COVID-19, RSV, and flu vaccines remain safe and effective